First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 32; no. 15_suppl; p. 7030
Main Authors Griffiths, Elizabeth A., Kantarjian, Hagop M., Roboz, Gail J., Kropf, Patricia Lamont, O'Connell, Casey Lee, Yee, Karen W. L., Garcia-Manero, Guillermo, Jabbour, Elias, Feldman, Eric Jay, Walsh, Katherine Jean, Rizzieri, David, Stock, Wendy, Lunin, Scott D., Naim, Sue, Choy, Gavin S., Taverna, Pietro, Hao, Yong, Azab, Mohammad, Chung, Woonbok, Issa, Jean-Pierre J.
Format Journal Article
LanguageEnglish
Published 20.05.2014
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.32.15_suppl.7030